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High-level evidence supports adjuvant radiotherapy for rectal cancer. We examined the influence of sociodemographic factors on
patterns of adjuvant radiotherapy for resected Stage II/III rectal cancer. Methods. Patients undergoing surgical resection for stage
II/III rectal cancer were identified in SEER registry. Results. A total of 21,683 patients were identified. Majority of patients were
male (58.8%), white (83%), and with stage III (54.9%) and received radiotherapy (66%). On univariate analysis, male gender, stage
III, younger age, year of diagnosis, and higher socioeconomic status (SES) were associated with radiotherapy. Radiotherapy was
delivered in 84.4% of patients <50; however, only 32.8% of those are >80 years. Logistic regression demonstrated a significant
increase in the use of radiotherapy in younger patients who are <50 (OR, 10.3), with stage III (OR, 1.21), males (OR, 1.18), and
with higher SES. Conclusions. There is a failure to conform to standard adjuvant radiotherapy in one-third of patients, and this is
associated with older age, stage II, area-level of socioeconomic deprivation, and female sex.
1. Introduction
In contrast to colon cancer, transmural (T3 andT4) andnode-
positive rectal cancer has a propensity for local recurrence.
Based on a significant morbidity of local-regional failure and
evidence from prospective randomized trials demonstrating
improvement in disease-free survival time and local-regional
recurrences [1], the National Cancer Institute sponsored
Consensus Conference convened in 1990 and recommended
that postoperative chemoradiotherapy should be adminis-
tered in all patients with stages II and III rectal cancers [2].
Despite these recommendations, adoption of these guidelines
into clinical practice has been, at best, uneven [3–6].
There is little debate that chemoradiotherapy reduces
local-regional failures and improves survival in stages II and
III rectal cancer.The SwedishRectal Cancer Trial randomized
patients to preoperative radiotherapy versus surgery alone.
The investigators demonstrated improved survival and local
control rate in patients receiving a short-course high-dose
preoperative radiotherapy [7]. The German Rectal Study
Group [8] randomly assigned patients with clinical stages II
and III rectal cancer to either preoperative or postoperative
chemoradiotherapy, and they provided convincing evidence
that preoperative chemoradiotherapy significantly improves
the local recurrence rate than postoperative chemoradiother-
apy. However, no difference in overall survival rate at 11 years
of follow-up was observed despite being adequately powered
to address this question [9]. Based on this compelling high
level evidence, the National Comprehensive Cancer Network
(NCCN) recommends radiotherapy (ideally preoperative) for
most patients with stage II/III rectal cancers [10].
We have previously demonstrated that significant num-
bers of patients undergoing curative surgical resection of
stage II/III rectal cancer do not receive radiotherapy [3,
6, 11]. It is imperative that patterns of care for patients in
whom guideline recommended radiotherapy is not delivered
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be understood. Omission of treatment in at-risk patients is
associated with outcome inequality [12, 13].This study sought
to examine, in a large population-based cancer registry,
adherence to National Cancer Institute Consensus guidelines
for the use of adjuvant radiotherapy in resected stage II/III
rectal cancer.
2. Methods
2.1. Data Source. This study utilized data obtained between
1998 and 2007 from the Surveillance Epidemiology and End
Results-(SEER-) 17 database. The SEER-17 program is the
largest population-based US cancer registry that collects
information on incidence, prevalence, and survival rate
from specific geographic areas representing 28% of the US
population. SEER routinely collects surgical and radiation
data but lacks any information on chemotherapy or site of first
recurrence.
2.2. Patients. We used the SEER-17 database for patients
diagnosed with rectal cancers. All patients were restaged
using current American Joint Committee on Cancer Criteria.
In this study, we included patients with either stage II or
stage III rectal cancer, those who had undergone curative
surgical resection of the primary tumor (site-specific surgery
codes 30, 40, 50, 60, 70, and 80), and those who were
documented to have either received or not received pelvic
radiation. Patients with SEER historic stage A disease with
nonregional metastatic disease at the time of diagnosis
(M1), or those who had missing treatment information (i.e.,
delivery of radiotherapywas not documented)were excluded.
The following variables were examined: age, race, gender,
year of diagnosis, delivery of radiotherapy, and county-level
census data (median family income, percent families below
poverty, percent high school education, percent unemployed,
and percent white-collar occupation).
2.3. Determination of Socioeconomic Status. We utilized a
validated index initially described by Robert et al. [14], which
is employed by others to define area-level socioeconomic
status (SES) in large databases. Three domains were defined
using the following county-level data: education (percent of
high school graduates), income (median income and percent
below poverty), and employment (percent unemployed and
percent white-collar occupation). Each factor was divided
into one of 5 quintiles, with one reflecting the lowest socioe-
conomic quintile. After the quintiles were clearly defined, an
overall SES index was derived by adding each factor; these
scores were again divided into quintiles to derive a score from
1 to 5, with one reflecting the lowest SES and five the highest
SES.
2.4. Statistical Analysis. Data was extracted utilizing
SEER∗Stat 7.0.5 using the case-listing function and exported
to the SAS platform JMP (SAS Institute Inc., Cary, NC,
USA) for analysis 𝜒2, and Student’s 𝑡-tests were utilized
where appropriate. Adjusted analysis was performed with
multivariate regression.
3. Results
3.1. Patient Characteristics. A total of 21,683 patients met
the inclusion criteria for this study. Table 1 summarizes the
demographics of the study patient population stratified by
whether or not they received radiation. Nearly one-third of
patients (32.3%) did not receive adjuvant radiotherapy. A
majority of patients had stage III disease (54.9%), were aged
>60 years (64.3%), white (83%), and males (58.8%).
Young patients were far more likely to receive radio-
therapy than older patients (𝑃 < 0.0001). Only 33.5% of
patients >80 years of age received adjuvant radiotherapy. In
contrast, 84.4% of patients <50 years of age received adjuvant
therapy. The percentage of patients who received adjuvant
radiotherapy decreased with each successive decade of life.
Other factors associated with the utilization of adjuvant
radiotherapy include patients with stage III disease (stage III,
70.6% versus stage II, 64.3%; 𝑃 < 0.0001) and gender (male,
70.3% versus female, 64.1%; 𝑃 < 0.0001). In addition, we
observed that patients residing in lower SES index counties
were less likely to receive adjuvant therapy than individuals
who resided in higher SES index counties. However, we were
unable to define any difference in the delivery of radiotherapy
between different racial groups.
3.2. Multivariate Analysis of Sociodemographic Factors. In
order to better understand factors associated with delivery of
adjuvant radiotherapy, a bivariate logistic regression analysis
was performed. Patients greater than 80 years old were sig-
nificantly less likely to be treated with adjuvant radiotherapy
than any other age group (Table 2). Comparing patients ≤50
to those ≥80, the likelihood of adjuvant radiotherapy was
10 times greater (odds ratio 10.3 and 𝑃 value 0.001). The
odds of being treated decrease progressively with increased
age. Patients with stage III rectal cancer were significantly
more likely to be treated with radiotherapy than those with
stage II disease (odds ratio 1.21 and 𝑃 value <0.0001). Men
were more likely to be treated than women (odds ratio 1.18
and 𝑃 value <0.0001). Socioeconomic status was also linked
to use of adjuvant radiotherapy. This association, although
statistically significant, was fairly modest. The chance of
receiving radiotherapy was approximately 10% greater for
patients residing in the highest SES level counties when
compared to the lowest. We also noted a trend over time
for an increase in use of radiotherapy, odds ratio of 1.41 for
treatment in 2007 when compared to 1998, 𝑃 = 0.001.
4. Discussion
The optimal management of a patient with rectal cancer
involves a multidisciplinary team whose members include
surgeons with expertise in total mesorectal excision (TME),
radiation oncologists, medical oncologists, and ancillary
support staff. Despite dramatic improvements in local control
and survival with the introduction of neoadjuvant and
adjuvant radiotherapy regimens, not all patients are treated
with radiotherapy [1, 7, 9]. Utilizing a large population-based
cancer registry, we report a failure to deliver radiotherapy in
one-third of patients with stage II/III rectal cancer. Older age,
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Table 1: Patient demographics of resected rectal cancer patients (SEER-17; 1998–2007).
Variable Total Radiation (%) No radiation (%) 𝑃 value
𝑁 21,684 14,696 (67.8) 6,988 (32.3)
Age, years <0.0001
<50 3,151 2,658 (84.4) 493 (15.7)
50–59 4,592 3,710 (80.8) 882 (19.2)
60–69 5,266 3,968 (75.3) 1,298 (24.7)
70–79 5,450 3,279 (60.2) 2,171 (39.8)
>80 3,224 1,080 (33.5) 2,144 (66.5)
Gender <0.0001
Male 12,756 8,972 (70.3) 3,784 (29.7)
Female 8,927 5,723 (64.1) 3,204 (35.9)
Race 0.3902
White 18,007 12,175 (67.6) 5,832 (32.4)
African-American 1,545 1,048 (67.8) 497 (32.2)
Others/unknown 2,131 1,446 (69.1) 647 (30.9)
Stage <0.0001
II 9,774 6,282 (64.3) 3,492 (35.7)
III 11,909 3,492 (35.7) 3,496 (29.4)
SES index <0.0001
1 4,969 3,286 (33.9) 1,683 (33.9)
2 4,468 2,953 (66.1) 1,515 (33.9)
3 4,378 3,093 (70.7) 1,285 (29.4)
4 3,465 2,344 (67.7) 1,121 (32.4)
5 4,403 3,019 (68.6) 1,384 (31.43)
Year of diagnosis <0.0001
1998 1,240 809 (65.2) 431 (34.8)
1999 1,180 789 (66.9) 391 (33.1)
2000 2,387 1,568 (65.7) 819 (34.3)
2001 2,422 1,541 (63.6) 881 (36.4)
2002 2,430 1,541 (63.6) 826 (34.0)
2003 2,375 1,563 (65.8) 812 (34.2)
2004 2,296 1,565 (65.8) 731 (31.8)
2005 2,459 1,710 (69.5) 749 (30.5)
2006 2,370 1,703 (71.9) 667 (28.1)
2007 2,524 1,843 (73.0) 681 (27.0)
stage II, area-level socioeconomic deprivation, and female
gender were associated with a decreased likelihood of adher-
ence to consensus guidelines.
We found that there was a linear decrease in the use
of radiotherapy with increasing age. Patients less than 50
years old were treated with radiotherapy in 84.4% of cases,
whereas only a third of patients greater than 80 years
old were treated. This finding was maintained on logistic
regression. Patients less than 50 were 10 times more likely to
be treated with radiotherapy when compared to those older
than 80 (Table 2). Ageism (reflected by undertreatment of
older patients) is well documented for colorectal cancer. Such
treatment differences are not explained by comorbidities or
poor tolerance of treatment regimens [15–17]. Older patients
generally derive a similar benefit from adjuvant therapy
and can tolerate such regimens [17–20]. Despite this, older
patients with colorectal cancer are less likely to be treated
with adjuvant therapy [16, 17, 21–24]. Omission of adjuvant
radiotherapy in older, medically fit rectal cancer patients may
compromise not only local recurrent but survival as well.
We found that men were more likely to be treated with
adjuvant radiotherapy. Men were treated in 70% of cases,
whereas women received radiation in only 64% of cases.
On logistic regression, this difference persisted, with nearly
a 20% increase in treatment for men compared to women.
This phenomenonof omission of adjuvant therapy forwomen
with colorectal cancer has been documented in both the
United States and The Netherlands [21, 25]. Since there is
no reason to expect that women would not derive a similar
treatment benefit, the reason of this difference is unclear.
Lower socioeconomic status is associated with treatment
and outcome disparities for patients with colorectal cancer
[26, 27]. We found area-level socioeconomic deprivation, as
reflected in a validated socioeconomic index, to be associated
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Table 2: Logistic regression of factors associated with radiation
delivery in rectal cancer patients undergoing surgery, SEER17 1998–
2007.
OR CI (95%) 𝑃 value
Age
<50 10.3 9.13–11.64 <0.0001
50–59 8.09 7.28–8.98 <0.0001
60–69 5.96 5.41–6.57 <0.0001
70–79 2.99 2.73–3.28 <0.0001
>80 1
Stage
II 1
III 1.21 1.14–1.29 <0.0001
Sex
Male 1.18 1.11–1.26 <0.0001
Female 1
SES index
1 1
2 0.97 0.89–1.07 0.5653
3 1.25 1.14–1.38 <0.0001
4 1.18 1.06–1.30 0.0015
5 1.11 1.01–1.22 0.0301
Year
1998 1
1999 1.08 0.91–1.3 0.3758
2000 1.04 0.89–1.12 0.6421
2001 0.96 0.82–1.12 0.5919
2002 1.07 0.91–1.24 0.4243
2003 1.08 0.92–1.25 0.3579
2004 1.13 0.97–1.32 0.1160
2005 1.20 1.02–1.40 0.023
2006 1.33 1.13–1.56 0.0004
2007 1.41 1.20–1.64 <0.0001
with decreased use of adjuvant therapy. These findings are
similar to other investigators who have noted a slower
integration of advances in medical treatment of colorectal
cancer for patients residing in counties with lower SES [26].
This slow adaptation of medical innovation has resulted in
increasing outcome inequality in regions with area-level SES
deprivation.
The lower treatment rates for stage II cancer reported
here may, in part, be appropriate. There is some controversy
regarding the treatment of T3N0 rectal carcinoma.Theremay
be little benefit to radiotherapy for patients with T3N0 rectal
cancer resected using total mesorectal excision with negative
radialmargins if there isminimal invasion of themesorectum
[28]. These factors are not documented in the SEER registry;
as a result, it is impossible to determine whether deviation
from standard radiotherapy was rational [29].
Although SEER data is not robust enough tomake defini-
tive conclusions regarding the effects of radiotherapy on sur-
vival, the potential impact of optimal local therapy on overall
survival rate should not be overlooked. Educational initia-
tives and/or centralization designed to improve the quality
of care for rectal cancer patients suggest that optimal local
therapy can impact not only local recurrence rates but also
overall survival rate.TheUniversity of Erlangen implemented
a strategy to improve the quality of surgery in rectal cancer
by routine use of standardized TME surgery.The 5-year local
recurrence rate after implementation decreased from 39.4%
to 9.1% and survival rate improved from 50% to 71% [30].
Quality initiatives in other studies have found that systematic
education regarding implementation of and adherence to
optimal surgical and adjuvant therapy guidelines significantly
improves survival rates [5, 31–33]. Educational programs
in The Netherlands, designed to increase the use of TME
and preoperative radiotherapy, were associated with a 9%
improvement in 5-year survival rates [33]. Similar results
were noted in British Columbia [34]. Jullumstro found that
decreased adherence to guidelines in Norwegian patients was
associated with an increase in local recurrence and mortality
[5]. These findings are not unique to rectal cancer. Women
with node-positive breast cancer are generally considered to
have systemic disease, but they derive survival benefit from
postmastectomy radiation [35, 36].
Rectal cancer is no longer a disease that is adequately
treated by surgery alone. A large body of evidence now sup-
ports the use of preoperative chemoradiotherapy in patients
with stage II/III disease along with TME. In this report,
utilizing a large population-based database, we demonstrate
that pelvic radiotherapy is omitted after presumably curative
surgery in one-third of cases. Undertreatment is associated
with increasing age, female gender, lower SES, and stage II
disease. Although limitations in the SEER registry (i.e., lack
of data on chemotherapy and comorbidities data) precluded
a definitive survival analysis, it is likely that interventions that
improve compliance with treatment guidelines will improve
survival in groups at-risk for undertreatment. These data
imply that adjuvant radiotherapy is a key quality indicator for
this disease.
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